Female sexual wellness: a judgment-free guide to desire, arousal, and comfort
You have wondered if something is wrong with you. Desire feels muted. Sex has become uncomfortable, or it takes longer to feel ready. The silence can make you assume you are the only one. You are not. These concerns deserve a respectful assessment, and evidence-based options depend on the cause, menopause status, medical history, medications, and whether the change causes distress.
- The difference between desire, arousal, and comfort, and why they are not the same thing
- What can quietly lower desire, from hormones to stress to medications
- What genitourinary syndrome of menopause (GSM) is and why sex can start to hurt
- What HSDD is, and the treatments that exist for it in 2026
Desire, arousal, and comfort are three different things
Desire, arousal, and comfort describe different parts of sexual experience. A change in one does not identify its cause. A clinician can ask about distress, pain, medications, relationship context, mental health, menopause status, and other contributors before discussing treatment.
Low desire usually has a reason, often more than one
Low desire can reflect more than one biological, psychological, interpersonal, or medication factor. ISSWSH recommends a biopsychosocial assessment before diagnosing HSDD or considering systemic testosterone. Distress and possible alternative explanations are part of that assessment. 4
Painful sex is common, and it is treatable
Pain during sex is a common concern, but it is not something to push through. Menopause-related GSM is one possible contributor; pelvic floor conditions, skin disorders, infection, endometriosis, and other causes can also matter. After estrogen-dependent breast cancer, ACOG recommends nonhormonal options first. Selected low-dose vaginal estrogen requires a risks-and-benefits discussion, with the oncologist included for someone taking an aromatase inhibitor. 1
When low desire causes real distress, there is a name for it
No systemic testosterone product is FDA-approved for women in the United States. ISSWSH supports consideration only for appropriately assessed HSDD, with off-label use, informed consent, and physiologic-range monitoring. Clinicians should monitor androgen effects and levels every 4 to 6 months once stable, and not continue beyond 6 months without meaningful benefit. Randomized-trial safety data beyond 24 months are unavailable. 4
Safety note
ISSWSH does not recommend compounded testosterone, pellets, intramuscular injections, or oral formulations for HSDD. Marketing a custom or ‘bioidentical’ product does not establish safety, effectiveness, or dose consistency. 4
Vyleesi is FDA-approved for premenopausal women with acquired, generalized HSDD not explained by another condition, relationship problems, or medication or drug effects. It is contraindicated with uncontrolled hypertension or known cardiovascular disease. A clinician reviews suitability and risks. 2
Treatment depends on the cause and the evidence
| Concern | Common causes | What a clinician may discuss | Worth knowing |
|---|---|---|---|
| Distressing low desire | Multiple possible contributors; HSDD requires a biopsychosocial assessment | For assessed postmenopausal HSDD, off-label systemic testosterone may be considered. 4 | Clinician monitoring is required; stop if no meaningful benefit by 6 months. 4 |
| Painful sex or dryness (GSM) | Menopause-related tissue change is one possible cause | After estrogen-dependent breast cancer, nonhormonal options come first. 1 | Low-dose vaginal estrogen needs shared decision-making when appropriate. 1 |
| Trouble with arousal | Pain, stress, medication effects, and other contributors may overlap | Assessment of comfort, medications, context, and possible medical causes | Arousal concerns do not by themselves identify one cause or treatment |
| Pain not tied to menopause | Pelvic floor tension, skin conditions, infection, endometriosis | Evaluation to find the cause | Not something to push through; the cause points to the fix |
| Desire change without sexual distress | May reflect normal variation or another factor | Raise a new or unexplained change with a clinician if concerned | Lack of distress alone does not rule out another health issue |
Be wary of the quick fixes online
Compounded testosterone preparations are not FDA-approved products. ISSWSH does not recommend compounded testosterone for HSDD because efficacy and safety data are lacking and product concentration can vary. A clinician should explain the evidence, formulation, monitoring, and alternatives before any off-label treatment. 4
How to raise this without the awkwardness
A solid evaluation starts with your story, told without flinching: what changed, when, whether it hurts, what medications you take, and how much it bothers you. From there a clinician sorts hormonal, physical, emotional, and medication causes. Lab tests are sometimes useful but are not the whole picture.
Prepare for a focused clinical conversation
Write down what changed, whether it causes distress, whether sex is painful, and which medicines or health changes came first. Ask the clinician what causes were assessed, what the FDA label or guideline supports, what risks apply, and how response and adverse effects will be followed.
Your hormones deserve better than guesswork
- Online visits with licensed physicians
- Estradiol, progesterone, HRT & sexual wellness
- Lab panels at member pricing
- FSA & HSA eligible with all plans
From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Sources
- ACOG. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer." December 2021. acog.org
- FDA. "Vyleesi (bremelanotide) Prescribing Information." 2019. accessdata.fda.gov
- FDA. Addyi prescribing information, December 2025. accessdata.fda.gov
- ISSWSH. ‘Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.’ Journal of Sexual Medicine. 2021. Accessed September 15, 2026. isswsh.org